Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study.

Urologic oncology·2017
Same author

Diagnostic Accuracy of <sup>64</sup>Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience.

Urology·2017
Same author

The Microbiome of the Prostate Tumor Microenvironment.

European urology·2017
Same author

Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study.

Urologic oncology·2017
Same author

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non-muscle-invasive Bladder Cancer.

Clinical genitourinary cancer·2017
Same author

Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer.

European urology·2017
Same journal

Overall Survival with [<sup>177</sup>Lu]Lu-PSMA-617 Versus [<sup>177</sup>Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World Analysis.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Toward a Biopsy-Free Diagnosis of Prostate Cancer: Potential of Combined <sup>18</sup>F-Flotufolastat PSMA PET and mpMRI.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

PSMA PET/CT-Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Erratum.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Live from 2026 SNMMI Annual Meeting in Los Angeles!

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
See all related articles

Related Experiment Video

Updated: Jan 3, 2026

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

593

Prostate-Specific Membrane Antigen-Guided Surgery.

Tobias Maurer1,2, Markus Graefen3, Henk van der Poel4

  • 1Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany t.maurer@uke.de.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|November 17, 2019
PubMed
Summary
This summary is machine-generated.

Prostate-specific membrane antigen (PSMA)-ligand PET imaging is revolutionizing prostate cancer care. PSMA-guided surgery offers new potential for lymph node dissection in both primary and recurrent prostate cancer cases.

Keywords:
fluorescenceimage-guided surgerylymph node dissectionprostate cancersalvage

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.6K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Related Experiment Videos

Last Updated: Jan 3, 2026

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

593
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.6K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Surgical Oncology

Background:

  • Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography (PET) has emerged as a powerful tool in prostate cancer management.
  • While its influence on treatment decisions is growing, the direct impact on patient outcomes requires further investigation.
  • PSMA-ligand imaging has enabled innovative applications, including image-guided surgery.

Purpose of the Study:

  • To review the potential of PSMA-guided surgery in prostate cancer.
  • To discuss the implications of PSMA-guided surgery for lymph node dissection in primary and recurrent prostate cancer.

Main Methods:

  • This is a review article, synthesizing existing literature and research on PSMA-guided surgery.
  • The review focuses on the application of PSMA-ligand imaging in surgical contexts.
  • Discussion includes implications for lymph node dissection strategies.

Main Results:

  • PSMA-guided surgery demonstrates significant potential for improving the precision of surgical interventions.
  • The technique shows promise in enhancing lymph node staging and removal in primary prostate cancer.
  • It also offers potential benefits for managing recurrent prostate cancer, particularly in lymph node dissection.

Conclusions:

  • PSMA-guided surgery represents a promising advancement in prostate cancer management.
  • Its application in lymph node dissection for both primary and recurrent disease warrants further clinical evaluation.
  • Continued research and technological development are crucial for optimizing its role in patient care.